Literature DB >> 19789070

Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Thierry Bordet1, Rebecca M Pruss.   

Abstract

Neuropathic pain syndromes arise from dysfunction of the nerve itself, through traumatic or nontraumatic injury. Unlike acute pain syndromes, the pain is long-lasting and does not respond to common analgesic therapies. Drugs that disrupt nerve conduction and transmission or central sensitization, currently the only effective treatments, are only modestly effective for a portion of the patients suffering from neuropathic pain and come with the cost of serious adverse effects. Neurodegeneration, as a reaction to nerve trauma or chronic metabolic or chemical intoxication, appears to be an underlying cause of neuropathic pain. Identifying mechanisms of neurodegeneration and designing neuroprotective therapies is an ambitious goal toward treating or even preventing the development of these disabling disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789070      PMCID: PMC5084287          DOI: 10.1016/j.nurt.2009.07.001

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  152 in total

1.  Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.

Authors:  Jacqueline A Pettersen; Gareth Jones; Catherine Worthington; Hartmut B Krentz; Oliver T Keppler; Ahmet Hoke; M John Gill; Christopher Power
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

Review 2.  Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Authors:  Rocio S Lopez-Diego; Howard L Weiner
Journal:  Nat Rev Drug Discov       Date:  2008-11       Impact factor: 84.694

3.  Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature.

Authors:  Michael C Rowbotham; Howard L Fields
Journal:  Pain       Date:  1989-11       Impact factor: 6.961

4.  Protection of sensory function in diabetic rats by Neotrofin.

Authors:  Nigel A Calcutt; Jason D Freshwater; Nils Hauptmann; Eve M Taylor; Andrew P Mizisin
Journal:  Eur J Pharmacol       Date:  2006-02-28       Impact factor: 4.432

5.  Description of a short-term Taxol-induced nociceptive neuropathy in rats.

Authors:  N Authier; J P Gillet; J Fialip; A Eschalier; F Coudore
Journal:  Brain Res       Date:  2000-12-29       Impact factor: 3.252

6.  Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.

Authors:  Giulia Bianchi; Giordano Vitali; Augusto Caraceni; Sabrina Ravaglia; Giuseppe Capri; Sante Cundari; Claudio Zanna; Luca Gianni
Journal:  Eur J Cancer       Date:  2005-08       Impact factor: 9.162

7.  Binding characteristics of SSR180575, a potent and selective peripheral benzodiazepine ligand.

Authors:  V Vin; N Leducq; F Bono; J M Herbert
Journal:  Biochem Biophys Res Commun       Date:  2003-10-24       Impact factor: 3.575

Review 8.  Regulation of hexokinase binding to VDAC.

Authors:  John G Pastorino; Jan B Hoek
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

9.  Possible enhancement of vincristine neuropathy by VP-16.

Authors:  M Thant; R J Hawley; M T Smith; M H Cohen; J D Minna; P A Bunn; D C Ihde; W West; M J Matthews
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

10.  muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits.

Authors:  J Ekberg; A Jayamanne; C W Vaughan; S Aslan; L Thomas; J Mould; R Drinkwater; M D Baker; B Abrahamsen; J N Wood; D J Adams; M J Christie; R J Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

View more
  6 in total

1.  Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model.

Authors:  Joel M Brittain; Rui Pan; Haitao You; Tatiana Brustovetsky; Nickolay Brustovetsky; Gerald W Zamponi; Wei-Hua Lee; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2012-01-01       Impact factor: 2.581

Review 2.  A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Authors:  Marie-Francoise Chesselet; Franziska Richter; Chunni Zhu; Iddo Magen; Melanie B Watson; Sudhakar R Subramaniam
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

3.  Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide.

Authors:  Weina Ju; Qi Li; Yohance M Allette; Matthew S Ripsch; Fletcher A White; Rajesh Khanna
Journal:  J Neurochem       Date:  2013-01-20       Impact factor: 5.372

4.  α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement.

Authors:  Lorenzo Di Cesare Mannelli; Lorenzo Cinci; Laura Micheli; Matteo Zanardelli; Alessandra Pacini; J Michael McIntosh; Carla Ghelardini
Journal:  Pain       Date:  2014-07-05       Impact factor: 6.961

5.  Progesterone prevents development of neuropathic pain in a rat model: Timing and duration of treatment are critical.

Authors:  Liliane J Dableh; James L Henry
Journal:  J Pain Res       Date:  2011-04-05       Impact factor: 3.133

6.  Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.

Authors:  Giovanna Morello; Antonio Gianmaria Spampinato; Francesca Luisa Conforti; Velia D'Agata; Sebastiano Cavallaro
Journal:  J Mol Neurosci       Date:  2017-02-24       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.